BACKGROUND: We developed a new anti-cancer treatment, which is a combination of chemotherapeutic agents and low electric field. In the present study we investigated its efficacy against prostate metastatic transgenic adenocarcinoma of mice (TRAMP). METHODS: Mice with 5, 10, and 13 mm in diameter intracutaneous tumors received Low Electric Field Cancer Treatment-Enhanced Chemotherapy (LEFCT-EC) with doxorubicin (10 mg/kg), and monitored for survival, and primary and metastatic tumors growth. RESULTS: The electric field increased the uptake of doxorubicin by TRAMP cells in vitro. In vivo use of LEFCT-EC reduced tumor size, prolonged survival, and cured 36-93% of the animals, dependent on treated tumor size. LEFCT-EC was more effective than surgery with or without chemotherapy. Part of the cured animals developed anti-tumor immunity and immunosuppression, significantly decreased the effectiveness of the treatment. CONCLUSION: Our results suggest that LEFCT-EC is an effective method for the destruction of metastatic prostate tumors.
BACKGROUND: We developed a new anti-cancer treatment, which is a combination of chemotherapeutic agents and low electric field. In the present study we investigated its efficacy against prostate metastatic transgenic adenocarcinoma of mice (TRAMP). METHODS:Mice with 5, 10, and 13 mm in diameter intracutaneous tumors received Low Electric Field Cancer Treatment-Enhanced Chemotherapy (LEFCT-EC) with doxorubicin (10 mg/kg), and monitored for survival, and primary and metastatic tumors growth. RESULTS: The electric field increased the uptake of doxorubicin by TRAMP cells in vitro. In vivo use of LEFCT-EC reduced tumor size, prolonged survival, and cured 36-93% of the animals, dependent on treated tumor size. LEFCT-EC was more effective than surgery with or without chemotherapy. Part of the cured animals developed anti-tumor immunity and immunosuppression, significantly decreased the effectiveness of the treatment. CONCLUSION: Our results suggest that LEFCT-EC is an effective method for the destruction of metastatic prostate tumors.